- Home
- LFST vs SRPT Comparison
LFST vs SRPT Comparison
Compare LFST & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- SRPT
- Stock Information
- Founded
- LFST 2015
- SRPT 1980
- Country
- LFST United States
- SRPT United States
- Employees
- LFST N/A
- SRPT N/A
- Industry
- LFST Medical/Nursing Services
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- LFST Health Care
- SRPT Health Care
- Exchange
- LFST Nasdaq
- SRPT Nasdaq
- Market Cap
- LFST 1.9B
- SRPT 2.0B
- IPO Year
- LFST 2021
- SRPT 1997
- Fundamental
- Price
- LFST $5.44
- SRPT $21.81
- Analyst Decision
- LFST Strong Buy
- SRPT Hold
- Analyst Count
- LFST 5
- SRPT 29
- Target Price
- LFST $8.60
- SRPT $45.65
- AVG Volume (30 Days)
- LFST 3.2M
- SRPT 19.4M
- Earning Date
- LFST 08-07-2025
- SRPT 08-06-2025
- Dividend Yield
- LFST N/A
- SRPT N/A
- EPS Growth
- LFST N/A
- SRPT N/A
- EPS
- LFST N/A
- SRPT N/A
- Revenue
- LFST $1,316,483,000.00
- SRPT $2,481,531,000.00
- Revenue This Year
- LFST $15.03
- SRPT $3.52
- Revenue Next Year
- LFST $13.83
- SRPT N/A
- P/E Ratio
- LFST N/A
- SRPT N/A
- Revenue Growth
- LFST 13.86
- SRPT 64.89
- 52 Week Low
- LFST $3.74
- SRPT $10.42
- 52 Week High
- LFST $8.61
- SRPT $144.22
- Technical
- Relative Strength Index (RSI)
- LFST 70.25
- SRPT 61.42
- Support Level
- LFST $3.81
- SRPT $17.28
- Resistance Level
- LFST $4.28
- SRPT $20.61
- Average True Range (ATR)
- LFST 0.24
- SRPT 1.62
- MACD
- LFST 0.21
- SRPT 1.05
- Stochastic Oscillator
- LFST 90.19
- SRPT 95.85
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.